Erin Sparrow - Concepedia

Author

Erin Sparrow

World Health Organization ORCID

Also Known As

Erin G Sparrow, Erin G. Sparrow, Erin Grace Sparrow, Erin Grace Sparrow Jones, Erin Sparrow, Joyce Nyiro

Publications

862

Citations

H-Index

Concepts

All Affiliations

World Health Organization Program for Appropriate Technology in Health Johns Hopkins University University of Edinburgh University of Maryland, Baltimore

About

Erin Sparrow is an author at World Health Organization specializing in vaccine development, medicine, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	176
2	Epidemiology	2	2	136
3	Public Health	1	1	102
4	Global Health	1	1	102
5	Immunology	1	1	34

Erin Sparrow

Publications

422

Citations

H-Index

Page 1

	Year	Citations
Global production capacity of seasonal and pandemic influenza vaccines in 2019 Erin Sparrow, James Wood, Christopher Chadwick, Vaccine VaccinationVaccine SafetyVaccine DevelopmentGlobal Production CapacityGlobal Health	2020	102
The 2015 global production capacity of seasonal and pandemic influenza vaccine Kenneth A McLean, Shoshanna Goldin, Claudia Nannei, Vaccine	2016	73
Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030 Mateusz Hasso-Agopsowicz, Angela Hwang, Maria-Graciela Hollm-Delgado, EBioMedicine	2024	46
H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial Larisa Rudenko, Irina Isakova–Sivak, Anatoly Naykhin, The Lancet Infectious Diseases VaccinologyVaccinationVaccine SafetyVaccine DevelopmentVaccine Efficacy	2015	40
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial Punnee Pitisuttithum, Kobporn Boonnak, Supat Chamnanchanunt, The Lancet Infectious Diseases	2017	34
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use Erin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, Vaccine VaccinationWorld Health OrganizationRespiratory Virus ImmunityVaccine DevelopmentPreventive Medicine	2022	34
Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model Larisa Rudenko, Irina Kiseleva, Elena Krutikova, PLoS ONE	2018	23
Value profile for respiratory syncytial virus vaccines and monoclonal antibodies Jessica A. Fleming, Ranju Baral, Deborah Higgins, Vaccine	2023	20
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022 Meagan C. Fitzpatrick, Rachel S. Laufer, Ranju Baral, Vaccine	2023	15
Global production capacity of seasonal and pandemic influenza vaccines in 2023 Jessica Taaffe, Shoshanna Goldin, Philipp Lambach, Vaccine	2025	14

Page 1